Mumbai, May 13, 2026 — Cipla Ltd. reported a 55% year-on-year fall in consolidated net profit to Rs 555 crore in Q4 FY26, down from Rs 1,222 crore in the same quarter last year, per a BSE regulatory filing released Wednesday. Revenue from operations declined 3% YoY to Rs 6,541 crore during the quarter.
Also Read: CIPLA NSE Stock Price Today: Live Share Price & Rate
Dividend Declared: Rs 13 Per Share, Record Date: June 5
Cipla’s board recommended a final dividend of Rs 13 per share for FY26, with a record date of June 5, 2026, per the BSE filing. The payout is consistent with prior years and signals the board is not treating this as a distress quarter, but it does not offset the margin compression investors are absorbing.
EBITDA Margin Halved — Worse Than Every Brokerage Estimate
The profit collapse runs deeper than the revenue slide suggests. EBITDA fell 35% to Rs 997 crore from Rs 1,538 crore a year ago, per Cipla’s BSE regulatory filing dated May 13, 2026 (bseindia.com/stock-share-price/cipla/cipla/500087). EBITDA margin contracted 760 basis points to 15.2% from 22.8% — the sharpest single-quarter margin erosion the company has reported in recent years. Motilal Oswal had estimated EBITDA at Rs 1,180 crore and ICICI Securities at Rs 1,087 crore. The actual came in worse than every brokerage on the street. That number, more than the headline profit figure, is what analysts will be circling.
North America Dragged the Quarter Down
The numbers tell the story directly. North America quarterly revenue dropped 26% YoY to Rs 1,414 crore from Rs 1,919 crore a year ago, a Rs 505 crore single-geography revenue loss in one quarter. Since North America carries Cipla’s highest margins among all geographies, that decline hit EBITDA disproportionately hard relative to its revenue share.
Cipla did not provide a specific breakdown for what drove the North America decline in its BSE filing. Generic pricing erosion across large-volume molecules has been an industry-wide pressure point, but the company offered no molecule-level detail in Wednesday’s disclosure.
The one concrete positive from the US: Cipla received regulatory approval for the first AB-rated generic version of gVentolin manufactured from its US facility. That is a pipeline milestone with meaningful FY27 revenue potential, gVentolin is a significant inhaler market, but it contributed nothing to Q4 numbers.
India Grew 15%—The Business Holding the Company Together
The One India business, covering prescription, trade generics, and consumer health, grew 15% year-on-year to Rs 3,007 crore in Q4 FY26, from Rs 2,622 crore in Q4 FY25, per the BSE filing. Sequentially, revenue declined from Rs 3,457 crore in Q3 FY26, a pattern consistent with Q4 seasonality in domestic pharma, where January–March typically sees lower institutional and government procurement versus October–December. Branded prescription therapies across respiratory, urology, anti-diabetes, and cardiac segments drove the year-on-year growth. Consumer health brands including Nicotex, Omnigel, and Cipladine held market leadership positions, per the filing.
One geography growing 15% while another drops 26% in the same quarter defines exactly where Cipla’s near-term earnings risk is concentrated.
Africa Was the Quarter’s Underreported Outperformer
The One Africa business posted 21% YoY revenue growth to Rs 1,236 crore. South Africa specifically jumped 33% to Rs 984 crore, a number that deserves more attention than it typically gets in results coverage dominated by US headlines.
Emerging Markets and Europe declined 9% YoY to Rs 819 crore. The API and other business segment was the quarter’s sharpest single-line deterioration, revenue fell 77% YoY to Rs 64 crore from approximately Rs 278 crore a year ago. Cipla did not provide an explanation for the API collapse in Wednesday’s filing. That absence of disclosure is itself a question the earnings call needs to answer.
Full Year FY26: Record Revenue, Deteriorating Profitability
For the full financial year, Cipla reported revenue of Rs 28,163 crore, up 2% YoY and the highest annual revenue in the company’s history, per Wednesday’s BSE filing. Achin Gupta, MD and Global CEO (Designate), Cipla, stated the company would continue focusing on flagship brands, pipeline investments, and regulatory resolutions. Gupta’s Designate suffix remains in place as of the May 13, 2026 filing; formal designation as MD and Global CEO is expected to be confirmed at the upcoming AGM. No specific FY27 revenue or margin guidance was provided in the filing.
The profitability picture is harder to defend. Annual PAT declined 26% to Rs 3,879 crore from Rs 5,273 crore in FY25. Full-year EBITDA fell 17% to Rs 5,925 crore, with margin narrowing 490 basis points to 21% from 25.9% last year. Record revenue with a 490 bps annual margin contraction is not a combination that sustains a premium valuation without a credible recovery narrative.
Stock Up — But Gains Fading
Cipla shares were trading 4% higher at Rs 1,344.90 on NSE as of 10:30 AM IST on Wednesday, May 13, 2026, following the results announcement. By 12:59 PM IST the stock had pared gains to Rs 1,324.2, per INDmoney live data. The stock had corrected 13.8% year-to-date heading into the result, suggesting the earnings miss was at least partially priced in before the filing hit. The gVentolin approval and India’s 15% growth likely gave investors a forward anchor to hold positions against the weak quarterly print.
What to Watch Next
The next hard trigger for the stock is Cipla’s formal earnings call, where management will face direct questions on the North America recovery timeline, the gVentolin launch ramp, what caused the 77% API segment collapse, and whether the 21% full-year EBITDA margin represents a new floor or a transitional trough. Achin Gupta’s FY27 margin guidance, when it comes, will move this stock more than any quarterly number already reported.
Read Next: Texmaco Rail Wins Rs 4,045 Crore South Africa Order; Q4 Profit Up 45%
Frequently Asked Questions
Q: What was Cipla’s revenue in Q4 FY26?
Revenue from operations was Rs 6,541 crore in Q4 FY26, down 3% YoY, per Cipla’s BSE regulatory filing dated May 13, 2026.
Q: Why did Cipla’s EBITDA margin fall so sharply in Q4 FY26?
EBITDA margin contracted 760 basis points to 15.2% from 22.8% a year ago, per the BSE filing. The primary driver was a 26% YoY drop in North America revenue to Rs 1,414 crore, a Rs 505 crore decline in Cipla’s highest-margin geography, compounded by a 77% collapse in API and other business revenue to Rs 64 crore. Both figures were worse than all brokerage estimates: Motilal Oswal had forecast EBITDA at Rs 1,180 crore and ICICI Securities at Rs 1,087 crore.
Q: What is Cipla’s dividend for FY26, and when is the record date?
Cipla declared a final dividend of Rs 13 per share for FY26. The record date for dividend payment is June 5, 2026, per the BSE filing.
Q: Did Cipla’s India business grow in Q4 FY26?
Yes. The One India business grew 15% YoY to Rs 3,007 crore in Q4 FY26, driven by branded prescription therapies and consumer health brands, including Nicotex, Omnigel, and Cipladine, per the company’s BSE filing.
